Aaron Samuel Breslow1,2, Nathaniel M Tran3, Frederick Q Lu3, Jonathan E Alpert4, Benjamin Lê Cook3,4,5. 1. Health Equity Research Laboratory, Department of Psychiatry, Cambridge Health Alliance, Cambridge, MA, USA. abreslow@montefiore.org. 2. PRIME Center for Health Equity, Psychiatry Research Institute at Montefiore Einstein, Department of Psychiatry and Behavioral Sciences, Albert Einstein College of Medicine, Bronx, NY, USA. abreslow@montefiore.org. 3. Health Equity Research Laboratory, Department of Psychiatry, Cambridge Health Alliance, Cambridge, MA, USA. 4. PRIME Center for Health Equity, Psychiatry Research Institute at Montefiore Einstein, Department of Psychiatry and Behavioral Sciences, Albert Einstein College of Medicine, Bronx, NY, USA. 5. Department of Psychiatry, Harvard Medical School, Boston, MA, USA.
Abstract
PURPOSE OF REVIEW: We review 2016-2019 peer-reviewed literature which summarizes the factors contributing to high expense of treating depression among adults in the USA, and interventions that have been conducted to decrease depression treatment expenditures. RECENT FINDINGS: Treatment expenditures associated with depression are high and growing, driven in part by increased health care utilization and a shift toward increased insurance coverage of medications and therapies. The majority of identified articles describe the elevated financial burden associated with treating individuals with chronic medical conditions who also have a depression diagnosis. The few available studies documenting health care system-level interventions identify that multi-target treatment for comorbid illness, collaborative care management, and integration of psychiatric treatment into primary care show promise for reducing depression treatment expenditures. Additional research is needed to identify innovative, cost-effective state, and federal payer-initiated depression treatment models, and evaluation of collaborative care and integrated care models implemented to scale across multiple health care systems.
PURPOSE OF REVIEW: We review 2016-2019 peer-reviewed literature which summarizes the factors contributing to high expense of treating depression among adults in the USA, and interventions that have been conducted to decrease depression treatment expenditures. RECENT FINDINGS: Treatment expenditures associated with depression are high and growing, driven in part by increased health care utilization and a shift toward increased insurance coverage of medications and therapies. The majority of identified articles describe the elevated financial burden associated with treating individuals with chronic medical conditions who also have a depression diagnosis. The few available studies documenting health care system-level interventions identify that multi-target treatment for comorbid illness, collaborative care management, and integration of psychiatric treatment into primary care show promise for reducing depression treatment expenditures. Additional research is needed to identify innovative, cost-effective state, and federal payer-initiated depression treatment models, and evaluation of collaborative care and integrated care models implemented to scale across multiple health care systems.
Entities:
Keywords:
Cost; Depression; Mental health care; United States
Authors: David G Beiser; Charlotte E Ward; Milkie Vu; Neda Laiteerapong; Robert D Gibbons Journal: Acad Emerg Med Date: 2019-04-07 Impact factor: 3.451
Authors: Sreeram Penna; Kerri L Bell; Feng-Chih Kuo; Robert Andrew Henderson; Carol Foltz; Antonia F Chen Journal: J Arthroplasty Date: 2019-01-24 Impact factor: 4.757
Authors: Robert T Ammerman; Jie Chen; Peter J Mallow; John A Rizzo; Alonzo T Folger; Judith B Van Ginkel Journal: J Affect Disord Date: 2015-10-27 Impact factor: 4.839
Authors: Nathalie Moise; Ravi N Shah; Susan Essock; Amy Jones; Jay Carruthers; Margaret A Handley; Lauren Peccoralo; Lloyd Sederer Journal: Implement Sci Date: 2018-10-12 Impact factor: 7.327